Similar outcome for cryopreserved embryo transfer following GnRH-antagonist/GnRH-agonist, GnRH-antagonist/HCG or long protocol ovarian stimulation

Reproductive BioMedicine Online

Volumn 14, Issue 2, 2007, Pages 148-154

  Eldar Geva, Talia ^a   Zylber Haran, Edit ^a   Babayof, Rachel ^a   Halevy Shalem, Tamar ^a   Ben Chetrit, Avraham ^a   Tsafrir, Avi ^a   Varshaver, Irit ^a   Brooks, Baruch ^a   Margalioth, Ehud J ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Cryopreservation; Frozen thawed embryo transfer; GnRH agonist; GnRH antagonist; IVF; Pregnancy rate

Indexed keywords

CETRORELIX; ESTROFEM; HUMAN MENOPAUSAL GONADOTROPIN; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; TRIPTORELIN;

ADULT; ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; EMBRYO DEVELOPMENT; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; FREEZE THAWING; HUMAN; MAJOR CLINICAL STUDY; NIDATION; OOCYTE MATURATION; OVULATION INDUCTION; PREGNANCY RATE; RETROSPECTIVE STUDY; SURVIVAL RATE;

EID: 33847236962     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)60781-X     Document Type: Article

References (38)

1. Albano C, Felberbaum RE, Smitz J et al. 2000 Controlled ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the LHRH-antagonist Cetrorelix (Cetrotide) and the LHRH-agonist Buserelin. Human Reproduction 15, 26-31.
2. Al-Inany H, Aboulghar M 2002 GnRH antagonist in assisted reproduction: a Cochrane review. Human Reproduction 17, 874-885.
3. Asimakopoulos B, Nikolettos N, Al-Hasani S 2002 Outcome of cryopreserved pronuclear oocytes obtained after ovarian stimulation with either HMG or recFSH and the GnRH-antagonist cetrorelix. Reproductive Biomedicine Online 5 (Suppl. 1) 52-56.
4. Babayof R, Margalioth EJ, Huleihel M et al. 2006 Serum inhibin A, VEGF and TNFα levels after triggering oocyte maturation with GnRH-agonist compared to hCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Human Reproduction 21, 1260-1266.
5. Beckers NG, Macklon NS, Eijkemans MJ et al. 2003 Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. Journal of Clinical Endocrinology and Metabolism 88, 4186-4192.
6. Bodri D, Vernaeve V, Guillen JJ et al. 2006 Comparison between a GnRH antagonist and a GnRH agonist flare-up protocol in oocyte donors: a randomized clinical trial. Human Reproduction 21, 2246-2251.
7. Fauser BC, de Jong D, Olivennes F et al. 2002 Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. The Journal of Clinical Endocrinology and Metabolism 87, 709-715.
8. Felberbaum RE, Reissmann T, Kupker W et al. 1996 Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages. Journal of Assisted Reproduction and Genetics 13, 216-222.
9. Ferrari B, Pezzuto A, Barusi L, Coppola F 2006 Gonadotropin-releasing hormone antagonists increase follicular fluid insulin-like growth factor-I and vascular endothelial growth factor during ovarian stimulation cycles. Gynecological Endocrinology 22, 289-296.
10. Gabrielsen A, Fedder J, Agerholm I 2006 Parameters predicting the implantation rate of thawed IVF/ICSI embryos: a retrospective study. Reproductive BioMedicine Online 12, 70-76.
11. Griesinger G, Diedrich K, Devroey P, Kolibianakis EM 2006 GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Human Reproduction Update 12, 159-168.
12. Hu Y, Maxson WS, Hoffman DI et al. 1998 Maximizing pregnancy rates and limiting higher-order multiple conceptions by determining the optimal number of embryos to transfer based on quality. Fertility and Sterility 69, 650-657.
13. Humaidan P, Bredkjaer HE, Bungum L et al. 2005 GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Human Reproduction 20, 1213-1220.
14. Itskovitz-Eldor J, Kol S, Mannaerts B 2000 Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Human Reproduction 15, 1965-1968.
15. Kol S, Lightman A, Hillensjo T et al. 1999 High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles. Human Reproduction 14, 2242-2244.
16. Kolibianakis EM, Collins J, Tarlatzis BC et al. 2006 Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Human Reproduction Update. [e-publication ahead of print].
17. Kolibianakis EM, Schultze-Mosgau A, Schroer A et al. 2005 A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Human Reproduction 20, 2887-2892.
18. Lindheim SR, Morales AJ 2003 GnRH antagonists followed by a decline in serum estradiol results in adverse outcomes in donor oocyte cycles. Human Reproduction 18, 2048-2051.
19. Loutradis D, Stefanidis K, Drakakis P et al. 2004 A modified gonadotropin-releasing hormone (GnRH) antagonist protocol failed to increase clinical pregnancy rates in comparison with the long GnRH protocol. Fertility and Sterility 82, 1446-1448.
20. Ludwig M, Felberbaum RE, Devroey P et al. 2000 Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix in controlled ovarian stimulation for assisted reproduction. Archives of Genecology and Obstetrics 264, 29-32.
21. Mandelbaum J, Menezo YJ 2001 Cryopreservation of human embryos. In: Gardner DK, Howles DM, Weissman A, Shoham Z (eds) Textbook of Assisted Reproductive Techniques: Laboratory and Clinical Practices. Martin Dunitz, London, pp. 243-256.
22. Nevo O, Eldar-Geva T, Kol S, Itskovitz-Eldor J 2003 Lower levels of inhibin A and pro-alphaC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human chorionic gonadotropin. Fertility and Sterility 79, 1123-1128.
23. Nikolettos N, Al-Hasani S, Felberbaum R et al. 2000 Comparison of cryopreservation outcome with human pronuclear stage oocytes obtained by the GnRH antagonist, cetrorelix, and GnRH agonists. European Journal of Obstetrics, Gynecology and Reproductive Biology 93, 91-95.
24. Oehninger S, Mayer J, Muasher S 2000 Impact of different clinical variables on pregnancy outcome following embryo cryopreservation. Molecular and Cellular Endocrinology 169, 73-77.
25. Prapas N, Prapas Y, Panagiotidis Y et al. 2005 GnRH agonist versus GnRH antagonist in oocyte donation cycles: a prospective randomized study. Human Reproduction 20, 1516-1520.
26. Ragni G, Vegetti W, Riccaboni A et al. 2005 Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Human Reproduction 20, 2421-2425.
27. Saadat P, Boostanfar R, Slater CC et al. 2004 Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists. Fertility and Sterility 82, 167-171.
28. Seelig AS, Al-Hasani S, Katalinic A et al. 2002 Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle. Fertility and Sterility 77, 472-475.
29. Simon C, Oberye J, Bellver J et al. 2005 Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles. Human Reproduction 20, 3318-3327.
30. Stachecki JJ, Cohen J, Munne S. 2005 Cryopreservation of biopsied cleavage stage human embryos. Reproductive Biomedicine Online 11, 711-715.
31. Steer CV, Mills CL, Tan SL, et al. 1992 The cumulative embryo score: a predictive embryo scoring technique to select the optimal number of embryos to transfer in an in-vitro fertilization and embryo transfer programme. Human Reproduction 7, 117-119.
32. Tarlatzis BC, Kolibianakis EM. 2002 Direct ovarian effects and safety aspects of GnRH agonists and antagonists. Reproductive BioMedicine Online 5, 8-13.
33. Tarlatzis BC, Fauser BC, Kolibianakis EM et al. 2006 GnRH antagonists in ovarian stimulation for IVF. Human Reproduction Update 12, 333-340.
34. Veeck LL 1991 Atlas of human oocyte and early conceptus. Williams and Wilkins, Baltimore, USA. pp. 257-303.
35. Vlahos NF, Bankowski BJ, Zacur HA et al. 2005 An oocyte donation protocol using the GnRH antagonist ganirelix acetate, does not compromise embryo quality and is associated with high pregnancy rates. Archives of Gynecology and Obstetrics 272, 1-6.
36. Wang JX, Yap YY, Matthews CD 2001 Frozen-thawed embryo transfer: Influence of clinical factors on implantation rate and risk of multiple conception. Human Reproduction 16, 2316-2319.
37. Weiss JM, Oltmanns K, Gurke EM et al. 2001 Actions of gonadotropin-releasing hormone antagonists on steroidogenesis in human granulosa lutein cells. European Journal of Endocrinology 44, 677-685.
38. Zikopoulos K, Kolibianakis EM, Camus M et al. 2004 Duration of gonadotropin-releasing hormone antagonist administration does not affect the outcome of subsequent frozen-thawed cycles. Fertility and Sterility 81, 473-475.